In November, a panel of GSK executives and external experts heard presentations from the majority of its 38 groups of scientists, known internally as Discovery Performance Units, or DPUs. Scientists from each unit presented their plans for developing projects over the next three years and GSK plans to distribute the funding based on the outcome of these reviews. Britain’s largest drugs group is not expected to provide details on the outcome of its DPU review, but should reveal how many units secured an increase in funding and how many will see a reduction at its full-year results presentation on Tuesday.
